PRIMARY AGE-RELATED TAUOPATHY: BIOLOGICAL DEFINITION AND LONGITUDINAL CLINICAL OUTCOME

Jin-Tai Yu,Jie-Qiong Li,John Suckling,Qiang Dong,Lan Tan,Yanjiang Wang,Can Zhang

DOI: https://doi.org/10.1016/j.jalz.2019.06.3878

2019-01-01

Abstract:The condition of predominantly medial temporal lobe tauopathy with no or only minimal beta-amyloid (Aβ) deposition, should be considered a “primary age-related tauopathy” (PART). However, currently PART cannot be diagnosed in a living person, but only by autopsy. Moreover, the previous prevalence is presently unknown and the clinico-pathological spectrum of PART has also yet to be described with longitudinal clinical data. We performed biological characterization of PART according to the “ATN system” proposed in 2016. We included non-demented older individuals with available baseline cerebrospinal fluid (CSF) Aβ (normal: A-, abnormal: A+), CSF phosphorylated tau (p-tau) examination (T-/T+) and 18F-fluorodeoxyglucose (FDG) PET or volumetric magnetic resonance imaging (MRI) or CSF total-tau analysis (N-/N+) from ADNI. To evaluate how clinical outcomes changed overtime, we used linear mixed-effects models. To access the risk of progression, we constructed un-adjusted Kaplan-Meier plots. We also used multivariate Cox proportional hazard models. A-T+N± were defined as PART pathology. We found that from age 55 years, A−T+N− prevalence declined and A-T+N+ prevalence increased. Hippocampal atrophy was observed in all the three profiles either in CN or mild cognitive impairment (MCI) group; however, cognitive impairment was only observed in A-T+N+. A-T+N+ showed a faster rate of memory loss than A-T-N- and A-T+N-. Among the individuals with PART, there was no gender difference in the clinical outcomes. Compared with A-T-N-, participants with A-T+N- and A-T+N+ had increased risks of conversion from CN to symptomatic PART, and conversion from MCI to AD dementia, either in MCI or CN individuals. In summary, we propose a biomarker-based conceptualization of PART and report the prevalence and longitudinal clinical outcomes of PART biomarker profiles. The findings from clinical, imaging and biomarker studies in combination on PART have offered an important foundation for future studies.